Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380375 | 0.84 | CYP2A6 (0.50) | CYP2A6HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL1513823 | 0.83 | CYP2A6 (0.48) | CYP2A6HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL28152739 | 0.83 | BACE1 (0.50) | CYP2A6HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL27749305 | 0.81 | CYP2A6 (0.46) | CYP2A6HDAC4HDAC2HDAC8HDAC6 | |
| Methane SCHEMBL28112790 | 0.81 | BACE1 (0.48) | CYP2A6HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL1696360 | 0.80 | CYP2A6 (0.50) | CYP2A6BACE1ALOX5ALDH1A1CLCN2 | |
| SCHEMBL29983843 | 0.79 | AHR (0.60) | CYP2A6BACE1ALOX5ALDH1A1CLCN2 | |
| SCHEMBL381602 | 0.79 | AHR (0.60) | CYP2A6BACE1ALOX5ALDH1A1CLCN2 | |
| SCHEMBL31434466 | 0.79 | CYP2A6 (0.45) | CYP2A6HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL28545688 | 0.79 | ESR2 (0.50) | CYP2A6HDAC4HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | claimed |
| EP-1494995-B1 | 3-AMINOPHENOL DERIVATIVES SUBSTITUTED IN THE 2-POSITION, AND DYES CONTAINING THESE COMPOUNDS | PROCTER & GAMBLE (US) | 2010-09-22 | — | — | EP | claimed |
| WO-2019143110-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME | 주식회사 두산 | 2019-07-25 | — | — | WO | disclosed |
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | CYP2A6 481/4885HDAC4 2133/4885HDAC2 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.